Pfizer and BioNTech announce submission of phase 1 data to FDA to support booster dose of COVID-19 vaccine
Phase 1 safety &immunogenicity data are reported to show favourable safety profile & robust immune responses, with booster dose eliciting significantly higher neutralizing antibody titres against wild-type, and Beta & Delta variants vs. levels observed after 2-dose primary series
Source:
Biospace Inc.
SPS commentary:
The companies suggest that based on the high levels of immune responses observed, a booster dose given within 6 to 12 months after the primary vaccination schedule may help maintain a high level of protection against COVID-19. These data will also be submitted to the European Medicines Agency in the coming weeks.